Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives. We are committed to advancing the field of adeno-associated virus (AAV) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production.
Voyager's Dinah Sah and Rob Kotin Honored Among PharmaVOICE 100 Most Inspiring People
June 26, 2014
Voyager Therapeutics Appoints Industry Veteran Robert G. Pietrusko, Pharm.D., to Senior Vice President of Regulatory Affairs
June 2, 2014
ReGenX Biosciences and Voyager Therapeutics Announce License Agreement